Caris & Company Downgrades inVentiv Health (VTIV) to Average
More News related to VTIV
- inVentiv Health Companies Win Seven CLIO Healthcare Awards
- Repros Therapeutics (RPRX) Appoints Jaye Thompson to Board; Other Management Changes
- Repros Appoints Dr. Jaye Thompson to Board of Directors
- inVentiv Health (VTIV) Misses Q3 EPS by 9c
- inVentiv Health Reports Financial Results for Third Quarter 2009
Caris & Company downgrades inVentiv Health, Inc. (Nasdaq: VTIV) from Above Average to Average with a $20 price target.
inVentiv Health, Inc. provides value-added services to the pharmaceutical, life sciences, and healthcare industries in the United States, the United Kingdom, and France.
Related Categories
DowngradesStocks Mentioned
-0.28Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
